Wanbury reports strong Q2, H1 FY26 financial performance

Wanbury Limited reported a robust financial performance for Q2 and H1 FY26, with revenue from operations reaching ₹160.06 crore in Q2 FY26 and ₹323.2 crore in H1 FY26, marking a 10.57% year-over-year growth for H1 FY26. EBITDA for Q2 FY26 increased to ₹25.98 crore, a 20% year-over-year growth, with H1 FY26 EBITDA at ₹50.77 crore, representing a 51.26% year-over-year increase. Profit after Tax (PAT) for Q2 FY26 stood at ₹15.18 crore, an 89% year-over-year growth, and H1 FY26 PAT was ₹28.67 crore, a remarkable 216.45% year-over-year surge, reflecting improved cost efficiencies and product yields.

The API segment contributed ₹135 crore to Q2 FY26 revenue and ₹277 crore to H1 FY26 revenue, showing an 8.2% year-over-year growth for the half-year period. The formulations business also saw significant growth, with Q2 FY26 revenue at ₹22 crore and H1 FY26 revenue at ₹40 crore, up 17.6% year-over-year for H1 FY26. This turnaround in formulations is attributed to the successful launch of new brands and enhanced field productivity.

Wanbury's strategic initiatives include an expansion into regulated markets and the planned commercialization of new molecules, with 4 new additions expected each year starting FY27. The company's capital expenditure plan includes substantial investments in new clean room facilities and production blocks, aiming to sustain operational efficiencies and maintain high quality and compliance standards, reinforcing its position as a global pharmaceutical partner.